hPD-1/hCTLA-4

品系全名

C57BL/6JSmo-Pdcd1tm1(hPDCD1)Ctla4tm1(hCTLA4)Smoc

目录号

NM-HU-00079

品系状态

胚胎冻存

导出PDF

品系描述

通过hPD-1(NM-HU-00015)与hCTLA4(NM-HU-00014)交配获得。
应用领域:肿瘤研究;免疫治疗;药物筛选

验证数据

                         PD-1 expression in stimulated T cells

pd-1流式数据.png


10.png


图1 FACS 检测 PD-1&CTLA-4 双人源化纯合子小鼠人源 PD-1 和 CTLA-4 的表达。

结果显示在 PD-1&CTLA-4 双人源化纯合子小鼠可以检测到人源 PD-1 和 CTLA-4 的表达。

药效验证数据

131.jpg

图2 PD-1&CTLA-4 双人源化小鼠 MC38 荷瘤模型体内抗肿瘤药效验证。PD-1&CTLA-4 双人源化纯合子小鼠接种 MC38 人源化结肠癌细胞系,肿瘤生长至约 100 mm3 时,随机将动物分组为对照组和不同组合的治疗组(n=8)。

结果显示:针对人的 PD-1 抗体和 CTLA-4 抗体联合使用,与单独治疗组相比,有非常显著的抗肿瘤效果,证明 PD-1&CTLA-4 双人源化小鼠是一个很好的验证针对人 PD-1&CTLA-4 抗体联合药效的体内模型。

肿瘤二次接种生长数据

pd-1&ctla4 二次接种.jpg

图3.如图2所示,第1-4组的动物接受不同剂量的单药或联合治疗。 该图显示了治愈的G4小鼠体内植入肿瘤的进展,暗示了通过组合抗体治疗诱导的系统性抗肿瘤作用。



你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看